SCHEMBL18791006

SCHEMBL18791006

CC1CC=C(c2cncc(N3CCN(CC(=O)NC(C)C)CC3)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 9/20 0.42
▸ ALDH1A1 P00352 5/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ WNT1 P04628 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ PTPN11 Q06124 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ SLC27A1 Q6PCB7 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ CHRM5 P08912 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18790691 0.84 CYP11B2 (0.54) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL18791007 0.77 ALDH1A1 (0.46) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL23679949 0.76 CYP11B2 (0.46) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL22236774 0.75 ALDH1A1 (0.52) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL18791083 0.75 ALDH1A1 (0.52) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL18791082 0.74 CYP11B2 (0.68) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL18790986 0.72 CYP11B2 (0.65) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL22236820 0.68 ALDH1A1 (0.40) CYP11B2ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL12890282 0.66 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2TDP1KDM4EMAPT
SCHEMBL12082132 0.66 GFER (0.57) ALDH1A1SMN1; SMN2TDP1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3381904-B1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-07-28 — — EP disclosed
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-07-21 — — US disclosed
WO-2017069226-A1 NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717731-B2 Nitrogen-containing aromatic heterocyclic compound REN, NR3C2, NR5A1 CYP11B2 8/4885ALDH1A1 1495/4885SMN1; SMN2 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback